NYSE: BAXBaxter International Inc Stock
$29.81-0.85 (-2.77%)
Updated Jul 9, 2025
BAX Price
$29.81
Fair Value Price
N/A
Market Cap
$15.30B
52 Week Low
$26.25
52 Week High
$40.49
P/E
-27.1x
P/B
2.16x
P/S
1.47x
PEG
N/A
Dividend Yield
2.68%
Revenue
$11.89B
Earnings
-$560.00M
Gross Margin
36%
Operating Margin
-2.29%
Profit Margin
-4.7%
Debt to Equity
2.01
Operating Cash Flow
$663M
Beta
0.6
Next Earnings
Jul 24, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BAX Overview
Baxter International Inc. manufacturfes products to treat kidney disease and other chronic and acute medical conditions. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders, as well as plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions. Baxter's Medical Products segment produces intravenous and other products to deliver fluids and drugs to patients, inhalational anaesthetics, and contract manufacturing services. The company was founded in 1931 and is headquartered in Deerfield, IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BAX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
C
BAX
Ranked#8 of 45
Ranked#8 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.29 | A | |
| $10.60 | B | |
| $96.01 | B |
Be the first to know about important BAX news, forecast changes, insider trades & much more!
BAX News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BAX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BAX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BAX is good value based on its book value relative to its share price (2.16x), compared to the US Medical Instruments & Supplies industry average (3.69x)
P/B vs Industry Valuation
BAX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more BAX due diligence checks available for Premium users.
Valuation
BAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-27.1x
Industry
39.96x
Market
30.63x
BAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.16x
Industry
3.69x
BAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BAX's financial health
Profit margin
Revenue
$2.6B
Net Income
$126.0M
Profit Margin
4.8%
BAX's Earnings (EBIT) of -$272.00M... subscribe to Premium to read more.
Interest Coverage Financials
BAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.3B
Liabilities
$14.3B
Debt to equity
2.01
BAX's short-term assets ($7.04B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BAX's long-term liabilities ($10.77B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BAX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$193.0M
Investing
$3.3B
Financing
-$3.2B
BAX's operating cash flow ($663.00M)... subscribe to Premium to read more.
Debt Coverage Financials
BAX vs Medical Stocks
Baxter International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.